EA011951B1 - Иммуноглобулины против антигена ерсам - Google Patents

Иммуноглобулины против антигена ерсам Download PDF

Info

Publication number
EA011951B1
EA011951B1 EA200601386A EA200601386A EA011951B1 EA 011951 B1 EA011951 B1 EA 011951B1 EA 200601386 A EA200601386 A EA 200601386A EA 200601386 A EA200601386 A EA 200601386A EA 011951 B1 EA011951 B1 EA 011951B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
immunoglobulin
epcam
human immunoglobulin
serum
Prior art date
Application number
EA200601386A
Other languages
English (en)
Russian (ru)
Other versions
EA200601386A1 (ru
Inventor
Малте Петерс
Матиас Лохер
Надя Пранг
Корнелия Квадт
Original Assignee
Микромет Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Микромет Аг filed Critical Микромет Аг
Publication of EA200601386A1 publication Critical patent/EA200601386A1/ru
Publication of EA011951B1 publication Critical patent/EA011951B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EA200601386A 2004-02-13 2005-02-09 Иммуноглобулины против антигена ерсам EA011951B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/778,915 US20050180979A1 (en) 2004-02-13 2004-02-13 Anti-EpCAM immunoglobulins
PCT/EP2005/001307 WO2005080428A2 (en) 2004-02-13 2005-02-09 Anti-epcam immunoglobulins

Publications (2)

Publication Number Publication Date
EA200601386A1 EA200601386A1 (ru) 2007-06-29
EA011951B1 true EA011951B1 (ru) 2009-06-30

Family

ID=34838270

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601386A EA011951B1 (ru) 2004-02-13 2005-02-09 Иммуноглобулины против антигена ерсам

Country Status (23)

Country Link
US (3) US20050180979A1 (cg-RX-API-DMAC10.html)
EP (2) EP1713830B1 (cg-RX-API-DMAC10.html)
JP (1) JP5220315B2 (cg-RX-API-DMAC10.html)
KR (1) KR101236224B1 (cg-RX-API-DMAC10.html)
CN (1) CN1976951B (cg-RX-API-DMAC10.html)
AT (1) ATE437186T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005215874B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0507660A (cg-RX-API-DMAC10.html)
CA (1) CA2555694C (cg-RX-API-DMAC10.html)
DE (1) DE602005015544D1 (cg-RX-API-DMAC10.html)
DK (1) DK1713830T3 (cg-RX-API-DMAC10.html)
EA (1) EA011951B1 (cg-RX-API-DMAC10.html)
ES (1) ES2328159T3 (cg-RX-API-DMAC10.html)
IL (1) IL177069A (cg-RX-API-DMAC10.html)
MX (1) MXPA06008942A (cg-RX-API-DMAC10.html)
NO (1) NO339364B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ549125A (cg-RX-API-DMAC10.html)
PL (1) PL1713830T3 (cg-RX-API-DMAC10.html)
PT (1) PT1713830E (cg-RX-API-DMAC10.html)
SI (1) SI1713830T1 (cg-RX-API-DMAC10.html)
UA (1) UA87128C2 (cg-RX-API-DMAC10.html)
WO (1) WO2005080428A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200606083B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004068110A2 (en) 2003-01-24 2004-08-12 University Of Utah Methods of predicting mortality risk by determining telomere length
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
RU2434640C2 (ru) * 2006-02-09 2011-11-27 Микромет Аг Лечение метастатического рака молочной железы
EP1865001A1 (en) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Specific protease inhibitors and their use in cancer therapy
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
CN101970497B (zh) * 2007-04-04 2017-05-10 希格马托制药工业公司 抗‑EpCAM抗体及其用途
ES2433718T3 (es) 2008-12-22 2013-12-12 University Of Utah Research Foundation PCR multiplex monocromática cuantitativa
US20120252022A1 (en) * 2009-09-21 2012-10-04 Paul Walfish Methods and compositions for the diagnosis and treatment of thyroid cancer
EP2819695B1 (en) * 2012-03-02 2018-06-27 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
CN103387988B (zh) * 2012-09-24 2016-01-06 厦门大学 上皮细胞粘附分子的核酸适体EpCAM Ccut及其制备方法
JP6546158B2 (ja) 2013-05-22 2019-07-17 テロメア ダイアグノスティクス インコーポレイテッド 短いテロメアの存在量の測定
CN103275226B (zh) * 2013-06-09 2017-08-29 中国科学技术大学 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用
US11046763B2 (en) * 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2016108954A1 (en) 2014-12-30 2016-07-07 Telomere Diagnostics, Inc. Multiplex quantitative pcr
HUE054131T2 (hu) 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
CN110035768A (zh) 2016-07-26 2019-07-19 泰莎治疗私人有限公司 嵌合抗原受体
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
JP3876002B2 (ja) * 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
BR0209177A (pt) * 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
US20030175268A1 (en) * 2002-01-11 2003-09-18 Saint-Remy Jean-Marie R. Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
WO2003099205A2 (en) * 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEWIS L.D.: "Technology evaluation: ING-1, XOMA", CURRENT OPINION IN MOLECULAR THERAPEUTICS, vol. 5, no. 4, 2003, pages 433-436, XP008052075, UK, cited in the application, the whole document *

Also Published As

Publication number Publication date
NO339364B1 (no) 2016-12-05
NZ549125A (en) 2008-09-26
ZA200606083B (en) 2007-10-31
EP2107071A3 (en) 2009-12-30
EA200601386A1 (ru) 2007-06-29
JP2008500277A (ja) 2008-01-10
EP1713830B1 (en) 2009-07-22
US20070274982A1 (en) 2007-11-29
ES2328159T3 (es) 2009-11-10
PT1713830E (pt) 2009-10-19
EP2107071A2 (en) 2009-10-07
JP5220315B2 (ja) 2013-06-26
IL177069A0 (en) 2006-12-10
ATE437186T1 (de) 2009-08-15
US20120294873A1 (en) 2012-11-22
PL1713830T3 (pl) 2010-01-29
WO2005080428A3 (en) 2005-11-10
CA2555694A1 (en) 2005-09-01
IL177069A (en) 2010-11-30
US20050180979A1 (en) 2005-08-18
NO20064136L (no) 2006-11-07
HK1096103A1 (en) 2007-05-25
DK1713830T3 (da) 2009-10-12
MXPA06008942A (es) 2007-01-26
CN1976951B (zh) 2012-03-14
UA87128C2 (ru) 2009-06-25
BRPI0507660A (pt) 2007-07-17
KR101236224B1 (ko) 2013-02-22
AU2005215874B2 (en) 2011-01-27
KR20070009988A (ko) 2007-01-19
WO2005080428A2 (en) 2005-09-01
EP1713830A2 (en) 2006-10-25
SI1713830T1 (sl) 2009-10-31
AU2005215874A1 (en) 2005-09-01
DE602005015544D1 (de) 2009-09-03
CA2555694C (en) 2013-04-16
CN1976951A (zh) 2007-06-06

Similar Documents

Publication Publication Date Title
US12286480B2 (en) Modulators of ROR1-ROR2 binding
Abdulkadyrov et al. Sotatercept in patients with osteolytic lesions of multiple myeloma
US20120294873A1 (en) ANTI-EpCAM IMMUNOGLOBULINS
ZA200209815B (en) Aromatase inhibitors and monoclonal anti-HER2 antibodies as antitumors agents.
O'Donnell et al. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium‐DOTA‐peptide‐ChL6
US11648308B2 (en) Methods, regimens, combinations and antagonists
Kubo et al. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer
JP2022044827A (ja) 免疫媒介性がん治療のための組成物及び方法
KR20240168479A (ko) 건선 치료 방법
WO2019238713A2 (en) Treatments etc
Barete et al. Is lirentelimab the ‘magic bullet’to fight pathological mast-cell activation in systemic mastocytosis?
Schreiber et al. T1133 efficacy and tolerability of certolizumab pegol are sustained over 18 months: Data from PRECISE 2 and its extension studies (PRECISE 3 and 4)
Hanauer et al. T1130 Efficacy of Delayed-Release Oral Mesalamine in Patients Who Received Previous Ulcerative Colitis Treatment
Fasanmade et al. T1132 Pharmacokinetics and Exposure-Response Relationship of Ustekinumab, a Human Monoclonal Antibody to Interleukin 12/23, in Patients with Moderate-to-Severe Crohn's Disease
HK40102408A (en) Pharmaceutical composition containing anti-lag-3 antibody and application thereof
HK40102408B (en) Pharmaceutical composition containing anti-lag-3 antibody and application thereof
KR20260046144A (ko) 항-gfral 항체를 사용한 메스꺼움 및 구토 장애의 치료 방법
Hanauer et al. T1131 Steroid-Free Remission Over 2 Years in Crohn's Patients Receiving Adalimumab: the Open-Label Extension of the CHARM Trial
CN118946366A (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
Pfeiffer Denosumab for bone loss due to prostate & breast cancer therapies continuing to show promise
Warthan et al. A Psychocutaneous Approach to Sunbathing Behavior—Reply
HK1250999B (en) Modulators of ror1-ror2 binding

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU